KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash & Equivalents (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Cash & Equivalents for 8 consecutive years, with $70.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 47.11% to $70.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $70.5 million through Dec 2025, up 47.11% year-over-year, with the annual reading at $70.5 million for FY2025, 47.11% up from the prior year.
  • Cash & Equivalents hit $70.5 million in Q4 2025 for Adaptive Biotechnologies, up from $55.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $217.6 million in Q3 2022 to a low of $38.1 million in Q3 2024.
  • Historically, Cash & Equivalents has averaged $95.6 million across 5 years, with a median of $82.6 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: plummeted 75.38% in 2021 and later surged 77.74% in 2022.
  • Year by year, Cash & Equivalents stood at $139.1 million in 2021, then crashed by 35.26% to $90.0 million in 2022, then dropped by 27.73% to $65.1 million in 2023, then decreased by 26.35% to $47.9 million in 2024, then soared by 47.11% to $70.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for ADPT at $70.5 million in Q4 2025, $55.0 million in Q3 2025, and $43.2 million in Q2 2025.